▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #390 by analyst upside · 2026-09-27
CANF
Can-Fite BioPharma Ltd.
Healthcare · Market Cap $5M · P/E 0x
ANALYST PRICE TARGET
+270.0%
implied upside to consensus target
Current Price $2.16
Consensus Target $8.0
Bull Target $8.0
Bear Target $8.0
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $2.15
52-Week High $12.8
YTD Return -50.9%
FUNDAMENTALS
Market Cap $5M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.65
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.15
52-Week High $12.8
Current Price $2.16
Bear Target $8.0
Bull Target $8.0
● Now $2.16 ● Target $8.0
TRADING DATA
Avg Volume 1.4M
YTD Return -50.9%
Analyst Count 1
Consensus Buy
Upside to Target +270.0%
Last Updated 2026-09-27

ANALYST SUMMARY

Can-Fite BioPharma Ltd. (CANF) is currently trading at $2.16 with a Wall Street consensus price target of $8.0, implying potential upside of 270.0% over the next 12 months. 1 analysts currently cover CANF, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $8.0, while the most cautious has a target of $8.0.

CANF operates in the Healthcare sector with a market capitalisation of $5M. The stock is down 50.9% year-to-date and is currently trading near the lower end of its 52-week range of $2.15 – $12.8.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CANF, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-07-02 31% win rate (48 calls)
D. Boral Capital ↑ Upgrade
Hold → Buy 2026-05-13 32% win rate (25 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-12 31% win rate (48 calls)
D. Boral Capital ↓ Downgrade
Buy → Hold 2025-12-24 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-12-17 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-11-18 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-09-16 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-09-02 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →